Under the Paperwork Reduction Act of 1995, no perso to a collection of information unless it contains a valid OMB control number.

	Application Number		10728529	
	Filing Date		2003-05-12	
NFORMATION DISCLOSURE	First Named Inventor Tome		noyuki FUNAKI	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		2174	
not for submission under or or it may	Examiner Name LEE		E et al.	
	Attorney Docket Numb	er	YAMA:060	

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E)ate	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	6545208	B2	2003-04	I-08	HIRATSUKA		соптев .	Office Action issued in JP app no: 2002-353519 10/16/2006	
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1								Add	
If you wisi	n to a	dd additional U.S. Publ						d button	Remove	
	_		_	FOREIG	SN PAT	ENT DOCUM	IENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т.
	1	2002-258837	JP		A	2002-09-11	HIRATSUKA	1	Cited in Office Action ssued in corres JP app 2002-353519, mailed 10/16/2006, English abstract provided	
If you wish	h to a	dd additional Foreign P	atent Do	cument	citation	information p	lease click the Add	button	Add	
			NON	1-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite	Include name of the a (book, magazine, jour	nal, seri	al, symp	osium,	catalog, etc),				ТБ

publisher, city and/or country where published.

1	Office Action issued in corresponding Japanese application no: 2002-353519, mailed October 16, 2006.	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature | Date Considered |

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Not Code of USPTO Peter Documents at sew USETO CODY or MPEP 90104. * Edited office that issued the document, by the bro-letter code (NPPO Standard ST3). **Standard ST3). **Standard ST30.***Standard ST30.***

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10728529		
Filing Date		2003-05-12		
First Named Inventor	Tomoyuki FUNAKI			
Art Unit		2174		
Examiner Name	LEE et al.			
Attorney Docket Number		YAMA:060		

CERTIFICATION STATEMENT

Diagra can	37	CFR .	1 97	and	1 02	to make	the	appropriate	coloction/	e١٠

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- Na Na-

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Marc A. Rossi/	Date (YYYY-MM-DD)	2008-01-04
Name/Print	Marc A Rossi	Registration Number	31923

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the principal principal patients and the principal principal patients and the principal principal patients and the principal patients and the principal patients and the principal patients are patients. The principal patients are provided to the principal patients and the principal patients are patients. The principal patients are principally and the principal patients are principally as a patient of the patients and the principal patients are principally as a patient of the patients and the patients are provided to the patients and the patients are principally as a patient patients are principally as a patient patients and the patients are principally as a principal patient patients. The patients are patients are patients and the patients are patients and the patients are patients and the patients are patients. The patients are patients are patients are patients and the patients are patients and the patients are patients are patients. The patients are patients are patients are patients and the patients are patients are patients are patients. The patients are patients. The patients are patients are patients ar

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.